Defendant
4 cases as defendant.
Fresenius Kabi USA, LLC is a global healthcare company with its U.S. headquarters in Lake Zurich, Illinois. It operates as a subsidiary of Fresenius Kabi AG, which is a wholly owned operating company of the German healthcare group Fresenius SE & Co. KGaA (FSE: FRE). The parent company was founded in 1912, and the Fresenius Kabi division was formed in 1999. The global Fresenius Kabi entity employs over 40,000 people and reported sales of more than €8.5 billion in 2025. Fresenius Kabi USA has an estimated 1,001-5,000 employees.
Fresenius Kabi specializes in lifesaving medicines and technologies for infusion, transfusion, and clinical nutrition for critically and chronically ill patients. The company's product portfolio is divided into four main areas: Pharma, Biopharma, Nutrition, and MedTech. The Pharma division offers a wide range of intravenously administered generic drugs, including oncology, anesthesia, and anti-infective medications. The Biopharma segment focuses on developing biosimilars for autoimmune diseases and oncology. The Nutrition business provides parenteral and enteral nutrition products. The MedTech division offers medical devices such as infusion pumps, apheresis machines, and cell therapy technologies used in blood and plasma centers.
Based on the provided data, Fresenius Kabi USA, LLC is an operating company that acts as a defendant in patent litigation. It has been named as a defendant in four tracked cases and has not appeared as a plaintiff. All four suits were filed by the same entity, Haemonetics Corporation, in the U.S. District Court for the Northern District of Illinois, where Fresenius Kabi's U.S. headquarters is located. This litigation pattern is consistent with an operating company being sued for alleged infringement by another company in the same industry, rather than being targeted by a non-practicing entity (NPE).
The four tracked patent infringement cases were filed by Haemonetics Corporation on July 25, 2025, in the Northern District of Illinois. The lawsuits allege that Fresenius Kabi's Aurora Xi Plasmapheresis System infringes upon three Haemonetics patents. These patents relate to systems and methods for optimizing the collection of plasma from donors by more accurately determining the volume of pure plasma collected. The cases also name Fresenius Kabi AG and Fenwal, Inc. as co-defendants.
The complaint alleges that the defendants' Aurora Xi Plasmapheresis System infringes U.S. Patent No. 12,186,474, among other patents related to systems and methods for optimizing plasma collection.
Haemonetics alleges that the Aurora Xi Plasmapheresis System infringes upon three of its patents, including US patent 12,171,916. The case is currently active.
Haemonetics alleges that the defendants' Aurora Xi Plasmapheresis System infringes on its patents related to optimized plasma collection. The case is described as being connected to litigation involving the '416 patent family.
Haemonetics alleges that the Aurora Xi Plasmapheresis System infringes on U.S. Patent 10,758,652 and two other unspecified patents. The complaint highlights the patent's method for calculating the volume of pure plasma collected.